Synthesis Fe3O4@MCM-41-Urokinase Nano-Composite as an Advanced Drug Delivery System

Blood clots are one of the leading causes of death as a consequence of cardiovascular disease in the first place. Design and synthesis of new thrombolytic drugs is aimed at the prevention of side effects one of the important target in medicine. Herein, we report a novel nano-composite prepared by Urokinase with magnetite nanoparticles (Fe3O4@MCM-41-Urokinase). The magnetic nano-drug was prepared in three steps: (i) preparation of colloidal iron oxide magnetite nanoparticles (Fe3O4 MNPs) with particle size lower than 8.0 nm, (ii) development of an organic-inorganic MCM-41 mesoporous structure on the surface of MNPs (Fe3O4@MCM-41) and (iii) load the Urokinase on synthesized nano-composite surface (Fe3O4@MCM-41-Urokinase). The prepared organic-inorganic magnetic nano-drug was characterized by FT-IR (Fourier transform infrared spectroscopy), XRF (X-ray fluorescence), XRD (X-ray powder diffraction), TEM (Transmission electron microscopy) and VSM (Vibrating-sample magnetometer). The TEM image show, a large number of magnetite nanoparticles (2-5 nm) are dispersed in the structure of the siliceous mesoporous. shows excellent activity in the drug delivery in rats. The synthesized nano drug showed good stability to environmental factors. The drug delivery was evaluated in a group of 16 rats, the results showed that drug delivery in the presence of a magnetic field was successfully carried out.